Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection

16 Sept 2023

Abstract excerpt

SARS-CoV-2, the etiological agent behind the coronavirus disease 2019 (COVID-19) pandemic, has continued to mutate and create new variants with increased resistance against the WHO-approved spike-based vaccines. With a significant portion of the worldwide population still unvaccinated and with waning immunity against newly emerging variants, there is a pressing need to develop novel vaccines that provide broader...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37822719
DOI: 10.1016/j.omtm.2023.101110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionPMID 37822719Read ↗

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross- Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 VariantsSemantic proximity Read ↗

T Cell Responses to SARS-CoV-2Semantic proximity Read ↗

Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human PrimatesSemantic proximity Read ↗

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validationSemantic proximity Read ↗

T Cell Immune Responses to SARS-CoV-2 Infection and VaccinationSemantic proximity Read ↗

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansSemantic proximity Read ↗

A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccinesSemantic proximity Read ↗

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale ImmunitySemantic proximity Read ↗

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studiesSemantic proximity Read ↗

A pan-human coronavirus recombinant vaccine designed from conserved structural epitopes to counter emerging SARS-CoV-2 variantsSemantic proximity Read ↗

The T cell immune response against SARS-CoV-2.Semantic proximity Read ↗

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.